Index of drugs

Symptomatic treatment of inflammatory skin diseases that respond to topical treatment with glucocorticosteroids such as atopic dermatitis and psoriasis (excluding extensive psoriasis). Symptomatic treatment of inflammatory and psoriatic scalp diseases such as scalp psoriasis.

1 g of skin emulsion contains 1 mg mometasone furoate. The drug contains propylene glycol propionate.

Synthetic, nonfluorinated glucocorticosteroid for use on the skin, with a strong action (group III). It has a pronounced anti-inflammatory and anti-psorotic effect. Less than 1% of the active substance is absorbed by undamaged skin within 8 hours (without the use of an occlusive dressing). Determination of metabolites was impossible due to the small amounts of the drug present in the plasma and excretions.

Hypersensitivity to the active substance, other glucocorticoids or any of the excipients. Rosacea. Common acne. Atrophic skin changes. Inflammation of the skin around the mouth. Itching around the anus and genital area. Diaper rash. Bacterial infections (eg impetigo, purulent dermatitis), viral (eg herpes simplex, shingles, chicken pox, normal warts, condylomata acuminata, infectious mollusca) and fungal (eg yeast or dermatophyte infection). Parasitic skin infections (eg scabies). Tuberculosis. Syphilis. Post-vaccination reactions. Wounds or sores of the skin.

The product should not be used on the eyelid and avoid contact with eyes. If symptoms of irritation or sensitization occur after application, discontinue use and appropriate treatment. In case of skin infection, an appropriate antifungal or antibacterial drug should be used. If no improvement occurs within a short time, the glucocorticosteroid should be discontinued until the infection is cured. Systemic absorption of topical glucocorticosteroids may cause reversible suppression of the hypothalamo-pituitary-adrenal axis, with the possibility of posteroid adrenal insufficiency after discontinuation of treatment. In some patients during treatment with topical glucocorticosteroids, symptoms of Cushing's syndrome, hyperglycemia and glycosuria caused by systemic absorption may also occur. Children may be more susceptible to systemic toxicity of equivalent doses, due to the greater skin surface area ratio. Caution should be exercised when using the drug on large areas of the skin. Long-term therapy should be avoided regardless of the patient's age (increased risk of local or systemic side effects). The use of topical glucocorticoids in patients with psoriasis can be dangerous for a number of reasons, including due to rebound symptoms after the occurrence of tolerance, the risk of generalized pustular psoriasis and systemic or local toxicity due to impaired skin function as a protective barrier. If the emulsion is used in patients with psoriasis, it is important to closely monitor the patient. Sudden discontinuation of treatment (risk of rebound symptoms such as dermatitis) should be avoided. Glucocorticosteroids may change the appearance of some lesions and thus hinder proper diagnosis and delay the healing of lesions. The drug contains propylene glycol caprylate, which can cause skin irritation.

The drug can be used in pregnant and breastfeeding women only after careful consideration of the benefits of therapy to risk. Glucocorticoids penetrate the placenta. The interaction of high doses of glucocorticosteroids administered systemically to the embryo / fetus (intra-uterine retardation, suppression of the adrenal cortex, cleft palate) has been reported. Data on the topical use of mometasone during pregnancy are very limited. It is not known whether mometasone furoate is excreted in breast milk. When breastfeeding, do not apply to the breast area.In animal studies, reproductive and teratogenic effects of glucocorticoids have been shown to be toxic. The potential risk to humans is unknown.

Common: mild to moderate burning sensation at the application site, tingling / prickling sensation, pruritus, bacterial infections, paresthesia, irrigability, local skin atrophy. Uncommon: secondary infection; allergic contact dermatitis; stretch marks, irritation, hirsutism, hypopigmentation, perioral dermatitis, maceration of the skin, papillion-like skin inflammation (on the facial skin), acne-like changes, capillary frailty (spontaneous eclampsia), pricklyness, dryness, allergic reactions, folliculitis hair follicles. Very rare: teleangiectasia. Single (rare) cases of hypopigmentation or hyperpigmentation associated with the use of other glucocorticoids have been reported. During treatment with topical glucocorticosteroids, some patients may also experience side effects reported with systemic glucocorticosteroids, including adrenal suppression. Children may be more susceptible to hypothalamohypical-adrenal axis and Cushing's syndrome when treated with topical glucocorticosteroids. Chronic glucocorticoid treatment may interfere with the growth and development of children. Intracranial hypertension has been reported in children treated with topical glucocorticoids.

Locally. Adults (including elderly), adolescents and children ≥6 years: apply a few drops of emulsion to the affected areas (eg on the scalp) once a day, massage the emulsion thoroughly and gently until completely absorbed. The drug should not be used for a longer period (more than 3 weeks) or applied to large areas of the skin (over 20% of the body surface). In children, up to 10% of the body surface should be treated. The drug should not be used under the occlusive dressing or in the folds of the skin and on the face. After clinical improvement, it is often recommended to use a weaker glucocorticosteroid.